Treatment of Gram-negative bacterial infections by potentiation of antibiotics

Current Opinion in Microbiology

Volumn 33, Issue , 2016, Pages 7-12

  Zabawa, Thomas P ^a   Pucci, Michael J ^a   Parr, Thomas R ^a   Lister, Troy ^a  

^a Drug Product Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CATIONIC STEROID ANTIBIOTIC; OLIGO ACYL LYSYL; POLYMYXIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ANTIBACTERIAL ACTIVITY; DRUG POTENTIATION; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; KLEBSIELLA PNEUMONIAE; LIPOPHILICITY; MORBIDITY; MORTALITY; NONHUMAN; PERMEABILITY BARRIER; PSEUDOMONAS AERUGINOSA; REVIEW; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; COMBINATION DRUG THERAPY; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; POLYMYXINS;

EID: 84969597463     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2016.05.005     Document Type: Review

References (25)

1. Thabit A.K., Crandon J.L., Nicolau D.P. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother 2015, 16:159-177.
2. http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development.
3. Poole K. Outer membranes and efflux: the path to multidrug resistance in Gram-negative bacteria. Curr Pharm Biotechnol 2002, 3:77-98.
4. Hancock R.E.W., Wong P.G.W. Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother 1984, 26:48-52.
5. Gill E.E., Franco O.L., Hancock R.E.W. Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens. Chem Biol Drug Des 2015, 85:56-78.
6. Vaara M. Novel derivatives of polymyxins. J Antimicrob Chemother 2013, 68:1213-1219.
7. Vaara M. Polymyxins and their novel derivatives. Curr Opin Microbiol 2010, 13:574-581.
8. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev 1992, 56:395-411.
9. Vaara M., Vaara T. Sensitization of Gram-negative bacteria to antibiotics and complement by a non-toxic oligopeptide. Nature 1983, 303:526-528.
10. Ofek I., Cohen S., Rahmani R., Kabha K., Tamarkin D., Herzig Y., Rubinstein E. Antibacterial synergism of polymyxin B nonapeptide and hydrophobic antibiotics in experimental Gram-negative infections in mice. Antimicrob Agents Chemother 1994, 38:374-377.
11. Viljanen P., Vaara M. Susceptibility of gram-negative bacteria to polymyxin B nonapeptide. Antimicrob Agents Chemother 1984, 25:701-705.
12. Vaara M., Viljanen P. Binding of polymyxin B nonapeptide to gram-negative bacteria. Antimicrob Agents Chemother 1985, 27:548-554.
13. Rose F., Heuer K.U., Sibelius U., Hombach-Klonisch S., Kiss L., Seeger W., Grimminger F. Targeting lipopolysaccharides by the nontoxic polymyxin B nonapeptide sensitizes resistant Escherichia coli to the bactericidal effect of human neutrophils. J Infect Dis 2000, 182:191-199.
14. Duwe A.K., Rupar C.A., Horsman G.B., Vas S.I. In vitro cytotoxicity and antibiotic activity of polymyxin B nonapeptide. Antimicrob Agents Chemother 1986, 30:340-341.
15. Chihara S., Ito A., Yahata M., Tobita T., Koyama Y. Chemical synthesis, isolation and characterization of α-N-fattyacyl colistin nonapeptide with special reference to the correlation between antimicrobial activity and carbon number of fattyacyl moiety. Agric Biol Chem 1974, 38:521-529.
16. MacDonald E. Screening for drugsblocking acetylcholine-activated ion channels and local anaesthetics with the isolated chick biventer cervicis preparation. Pharmacol Toxicol 1988, 63:193-198.
17. Danner R.L., Joiner K.A., Rubin M., Patterson W.H., Johnson N., Ayers K.M., Parrillo J.E. Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob Agents Chemother 1989, 33:1428-1434.
18. Vaara M., Fox J., Loidl G., Siikanen O., Apajalahti J., Hansen F., Frimodt-Møller N., Nagai J., Takano M., Vaara T. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob Agents Chemother 2008, 52:3229-3236.
19. Vaara M., Siikanen O., Apajalahti J., Fox J., Frimodt-Møller N., He H., Poudyal A., Li J., Nation R.L., Vaara T. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob Agents Chemother 2010, 54:3341-3346.
20. Ali F.E., Cao G., Poudyal A., Vaara T., Nation R.L., Vaara M., Li J. Pharmacokinetics of novel antimicrobial cationic peptides NAB 7061 and NAB 739 in rats following intravenous administration. J Antimicrob Chemother 2009, 64:1067-1070.
21. Li C., Peters A.S., Meredith E.L., Allman G.W., Savage P.B. Design and synthesis of potent sensitizers of Gram-negative bacteria based on a cholic acid scaffolding. J Am Chem Soc 1998, 120:2961-2962.
22. Li C., Lewis M.R., Gilbert A.B., Noel M.D., Scoville D.H., Allman G.W., Savage P.B. Antimicrobial activities of amine- and guanidine-functionalized cholic acid derivatives. Antimicrob Agents Chemother 1999, 43:1347-1349.
23. Ding B., Guan Q., Walsh J.P., Boswell J.S., Winter T.W., Winter E.S., Boyd S.S., Li C., Savage P.B. Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics. J Med Chem 2002, 45:663-669.
24. Radzishevsky I.S., Rotem S., Bourdetsky D., Navon-Venezia S., Carmeli Y., Mor A. Improved antimicrobial peptides based on acyl-lysine oligomers. Nat Biotechnol 2007, 25:657-659.
25. Jammal J., Zaknoon F., Kaneti G., Goldberg K., Mor A. Sensitization of Gram-negative bacteria to rifampin and OAK combinations. Sci Rep 2015, 5:9216.